Daratumumab, sold under the brand name Darzalex, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed in multiple myeloma cells. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab. Daratumumab was granted breakthrough ... [wikipedia]
Darzalex Iv 100 mg/5ml Intravenous Injection, Solution, ConcentrateNDC: 57894-505
Janssen Biotech, Inc.